Trial Profile
A phase IIa study of MPC 3100 in patients with acute myeloid leukaemia.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 14 May 2012
Price :
$35
*
At a glance
- Drugs MPC 3100 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Myrexis
- 11 May 2012 Status changed from planning to suspended.
- 24 Nov 2011 New trial record